Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Stock Goes Ex-Dividend In Just Two Days
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Stock Goes Ex-Dividend In Just Two Days
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) stock is about to trade ex-dividend in two days. The ex-dividend date occurs one day before the record date which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Thus, you can purchase Shenzhen Mindray Bio-Medical Electronics' shares before the 7th of November in order to receive the dividend, which the company will pay on the 7th of November.
邁瑞醫療股票將在兩天後開始控件。 分紅除淨日比紀錄日早一天,該日爲股東需要在公司賬簿上登記以收取分紅的截止日。 分紅除淨日很重要,因爲任何股票交易都必須在紀錄日之前結算,才有資格獲得分紅。 因此,您可以在11月7日之前購買邁瑞醫療的股票,以便在11月7日收到公司支付的分紅。
The company's upcoming dividend is CN¥1.65 a share, following on from the last 12 months, when the company distributed a total of CN¥5.56 per share to shareholders. Last year's total dividend payments show that Shenzhen Mindray Bio-Medical Electronics has a trailing yield of 2.1% on the current share price of CN¥266.25. If you buy this business for its dividend, you should have an idea of whether Shenzhen Mindray Bio-Medical Electronics's dividend is reliable and sustainable. So we need to check whether the dividend payments are covered, and if earnings are growing.
公司即將派息1.65人民幣每股,繼續自上一年分配總額爲5.56人民幣每股的情況。 去年的總分紅顯示,邁瑞醫療在當前每股價格266.25人民幣上的滾動收益率爲2.1%。 如果您購買此業務是爲了獲得分紅,您應該了解邁瑞醫療的分紅是否可靠且可持續。 因此,我們需要檢查分紅支付是否得到覆蓋以及收益是否增長。
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Shenzhen Mindray Bio-Medical Electronics paid out 71% of its earnings to investors last year, a normal payout level for most businesses. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. It paid out 98% of its free cash flow in the form of dividends last year, which is outside the comfort zone for most businesses. Cash flows are usually much more volatile than earnings, so this could be a temporary effect - but we'd generally want to look more closely here.
分紅通常來自公司收益。如果一家公司支付的分紅超過了其利潤,那麼分紅可能是不可持續的。 邁瑞醫療去年向投資者支付了其收入的71%,這是大多數企業的正常分紅水平。 然而,現金流通通常比利潤更重要,用於評估分紅的可持續性,因此我們應始終檢查公司是否產生足夠的現金來支付其分紅。 去年,該公司以其自由現金流的98%形式支付了分紅,這對大多數企業來說超出了舒適區。 現金流通通常比利潤更具波動性,因此這可能是暫時影響-但我們通常會更仔細地審查這裏。
While Shenzhen Mindray Bio-Medical Electronics's dividends were covered by the company's reported profits, cash is somewhat more important, so it's not great to see that the company didn't generate enough cash to pay its dividend. Cash is king, as they say, and were Shenzhen Mindray Bio-Medical Electronics to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign.
雖然邁瑞醫療的分紅得到了公司報告的利潤的支持,但現金更爲重要,因此看到該公司未能產生足夠現金支付其分紅並不是好事。 衆所周知,現金爲王,如果邁瑞醫療反覆支付未能被現金流覆蓋的分紅,我們會認爲這是一個警告信號。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
點擊此處查看公司的支付比率以及未來分紅的分析師預期。
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. That's why it's comforting to see Shenzhen Mindray Bio-Medical Electronics's earnings have been skyrocketing, up 25% per annum for the past five years. Earnings have been growing quickly, but we're concerned dividend payments consumed most of the company's cash flow over the past year.
業務增長前景強勁的企業通常是最佳的分紅派息者,因爲當每股收益提高時,增加分紅更容易。投資者熱衷於分紅,所以如果收益下滑,分紅減少,股票也將會大幅拋售。因此,看到邁瑞醫療的收益一直在飆升,過去五年年均增長25%,這讓人感到欣慰。收益增長迅速,但我們擔憂去年分紅支付佔據了公司大部分現金流。
The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, six years ago, Shenzhen Mindray Bio-Medical Electronics has lifted its dividend by approximately 33% a year on average. It's exciting to see that both earnings and dividends per share have grown rapidly over the past few years.
大多數投資者評估公司的分紅前景的主要方式是查看歷史分紅增長率。自我們的數據開始六年前以來,邁瑞醫療每年分紅平均增長約33%。看到過去幾年收益和每股分紅都迅速增長令人振奮。
Final Takeaway
最後的結論
From a dividend perspective, should investors buy or avoid Shenzhen Mindray Bio-Medical Electronics? Earnings per share growth is a positive, and the company's payout ratio looks normal. However, we note Shenzhen Mindray Bio-Medical Electronics paid out a much higher percentage of its free cash flow, which makes us uncomfortable. In summary, it's hard to get excited about Shenzhen Mindray Bio-Medical Electronics from a dividend perspective.
從分紅派息的角度來看,投資者應該買入還是避開邁瑞醫療?每股收益增長是積極的,公司的派息比率看起來正常。然而,我們注意到邁瑞醫療支付了較高比例的自由現金流,這讓我們感到不安。總的來說,從分紅派息的角度看,很難對邁瑞醫療感到興奮。
So if you want to do more digging on Shenzhen Mindray Bio-Medical Electronics, you'll find it worthwhile knowing the risks that this stock faces. Our analysis shows 1 warning sign for Shenzhen Mindray Bio-Medical Electronics and you should be aware of this before buying any shares.
因此,如果您希望對邁瑞醫療進行更深入的研究,了解這支股票面臨的風險是值得的。我們的分析顯示邁瑞醫療有1個警示信號,您在購買任何股份之前應該意識到這一點。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。